Abstract Number: PB0597
Meeting: ISTH 2020 Congress
Background: The Lumira Dx is a point of care platform which uses cartridge based technology for INR testing in patients on VKA therapy.
Aims: To determine the suitability of UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) lyophilised plasma samples for use with Lumira Dx and to explore the possibility of establishing an external quality assessment (EQA) programme for this platform.
Methods: UK NEQAS BC conducted a study to determine suitability of NEQAS BC lyophilised plasma samples for Lumira Dx. After a series of testing using samples previously used in POC INR EQA programme a suitable diluent with an optimum time for sample reconstitution, calcium chloride concentration and volume was established. Precision was evaluated via repeated testing of an EQA sample previously used in POC INR programmes on three Lumira Dx platforms. This was followed by testing samples with increasing INR values previously used in POC INR programmes. Obtained results were compared to the POC INR sample specific medians established previously.
Results: A reasonable precision with CV% range 2.7 – 5.4 was observed across three platforms after repeated testing of a sample previously used in POC INR EQA programme (mean INR 3.0). The results of testing samples with increasing INR values previously used in POC INR EQA programmes are shown in the table. Obtained results on Lumira Dx were comparable to the sample specific medians established previously in POC INR programmes across three platforms.
Conclusions: In summary, Lumira Dx has demonstrated good precision (all < 10%) while testing NEQAS BC POC INR samples across three platforms. The study has demonstrated the suitability of NEQAS BC lyophilised plasma samples for testing on Lumira Dx. NEQAS BC can provide an EQA POC INR programme for this platform.
| Sample | POC EQA programme median INRs | Platform 1 | Platform 2 | Platform 3 |
| XS19:04 | 1.6 (n = 3703) | 1.8 | 2 | 1.9 |
| XS19:05 | 1.9 ( n =3754) | 2.1 | 2.1 | 2.1 |
| XS19:03 | 2.1 (n = 3698) | 2.3 | 2.6 | 2.4 |
| XS18:07 | 2.7 ( n= 3899) | 2.9 | 3.1 | 2.9 |
| XS19:06 | 3 (n = 3635) | 3.4 | 3.5 | 3.1 |
| XS18:01 | 5.7 (n = 3762) | 6.4 | 6.4 | 5.6 |
[Results of testing previously used samples in UK NEQAS POC INR programmes on Lumira Dx]
To cite this abstract in AMA style:
Brown L, Kitchen D, Jennings I, Kitchen S, Lowe A, Munroe - Peart S, Walker I. Evaluation of EQA Material on Lumira Dx Point of Care Platform: UK NEQAS for Blood Coagulation Study [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/evaluation-of-eqa-material-on-lumira-dx-point-of-care-platform-uk-neqas-for-blood-coagulation-study/. Accessed September 29, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-eqa-material-on-lumira-dx-point-of-care-platform-uk-neqas-for-blood-coagulation-study/